Strong Segmental Sales to Drive Cooper Companies Q4 Earnings?

Core Viewpoint - The Cooper Companies, Inc. is expected to report strong fourth-quarter fiscal 2024 results, with anticipated revenue growth and earnings improvement compared to the previous year [1][3][11]. Financial Estimates - The Zacks Consensus Estimate for revenues is projected at $1.03 billion, reflecting a 10.8% increase year-over-year [3]. - The consensus estimate for earnings is set at $1.00 per share, indicating a 15% improvement from the prior-year period [3]. Segment Performance - Cooper Companies operates under two main segments: CooperVision (CVI) and CooperSurgical (CSI), both of which have shown strength in recent quarters [4][10]. - CVI's revenues for Q4 are expected to range from $673 million to $685 million, representing organic growth of 8-10% [7]. - CSI's revenues are projected to be between $342 million and $350 million, indicating organic growth of 6-8% [10]. Growth Drivers - The demand for contact lenses has increased, particularly due to a global shift towards daily contact lenses, with CVI's lens business growing 13% in the Americas and 7% in both EMEA and Asia-Pacific [5]. - New product introductions, such as MyDay Energys and upgraded clariti multifocal, along with a successful back-to-school campaign, have contributed to increased consumption [6]. - CSI has benefited from strong demand for fertility and surgical products, particularly the PARAGARD device, and the company's new cryo management software and FastTrack genomics testing have aided sales [8][9]. Earnings Prediction - The company is predicted to beat earnings estimates, supported by a positive Earnings ESP of +1.25% and a Zacks Rank of 3 [11][12].